Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, van den Heuvel A, van der Gucht B, van Ranst M, van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, van Laethem K. Vercauteren J, et al. Among authors: schrooten y. AIDS Res Hum Retroviruses. 2008 Mar;24(3):355-62. doi: 10.1089/aid.2007.0212. AIDS Res Hum Retroviruses. 2008. PMID: 18327983
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.
Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme. Theys K, et al. Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81. Retrovirology. 2012. PMID: 23031662 Free PMC article.
Patterns of transmitted HIV drug resistance in Europe vary by risk group.
Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Wensing A; SPREAD Programme. Frentz D, et al. PLoS One. 2014 Apr 10;9(4):e94495. doi: 10.1371/journal.pone.0094495. eCollection 2014. PLoS One. 2014. PMID: 24721998 Free PMC article.
Performance of the VERSANT HIV-1 resistance assays (LiPA) for detecting drug resistance in therapy-naive patients infected with different HIV-1 subtypes.
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K, De Wit S, Fransen K, García Ribas S, Moutschen M, Vaira D, Zissis G, Van Ranst M, Van Wijngaerden E, Vandamme AM. Derdelinckx I, et al. Among authors: schrooten y. FEMS Immunol Med Microbiol. 2003 Nov 28;39(2):119-24. doi: 10.1016/S0928-8244(03)00240-2. FEMS Immunol Med Microbiol. 2003. PMID: 14625094 Free article.
Rising prevalence of HIV-1 non-B subtypes in Belgium: 1983-2001.
Snoeck J, Van Laethem K, Hermans P, Van Wijngaerden E, Derdelinckx I, Schrooten Y, van de Vijver DA, De Wit S, Clumeck N, Vandamme AM. Snoeck J, et al. Among authors: schrooten y. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):279-85. doi: 10.1097/00126334-200403010-00009. J Acquir Immune Defic Syndr. 2004. PMID: 15076243
Molecular testing of multiple HIV-1 transmissions in a criminal case.
Lemey P, Van Dooren S, Van Laethem K, Schrooten Y, Derdelinckx I, Goubau P, Brun-Vézinet F, Vaira D, Vandamme AM. Lemey P, et al. Among authors: schrooten y. AIDS. 2005 Oct 14;19(15):1649-58. doi: 10.1097/01.aids.0000187904.02261.1a. AIDS. 2005. PMID: 16184035
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Van Laethem K, De Munter P, Schrooten Y, Verbesselt R, Van Ranst M, Van Wijngaerden E, Vandamme AM. Van Laethem K, et al. Among authors: schrooten y. J Clin Virol. 2007 May;39(1):43-7. doi: 10.1016/j.jcv.2007.02.003. Epub 2007 Mar 21. J Clin Virol. 2007. PMID: 17369083
Limited cross-border infections in patients newly diagnosed with HIV in Europe.
Frentz D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme. Frentz D, et al. Retrovirology. 2013 Apr 3;10:36. doi: 10.1186/1742-4690-10-36. Retrovirology. 2013. PMID: 23551870 Free PMC article.
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.
Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme. Frentz D, et al. BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407. BMC Infect Dis. 2014. PMID: 25047543 Free PMC article. Clinical Trial.
32 results